
    
      OBJECTIVES: I. Determine the response rate (objective and PSA response) and duration of
      response to estramustine, docetaxel, and carboplatin with filgrastim (G-CSF) support in
      patients with hormone refractory prostate cancer. II. Determine the toxicity of this regimen
      in this patient population.
    
  